MONOCLONAL AND POLYCLONAL MEGAKARYOCYTE-CSF ANTIBODIES

从骨髓中的祖细胞产生巨核细胞可以 由一种谱系特异性因子-巨核细胞集落刺激刺激 因子(MEG-CSF)。巨核细胞的谱系特异性刺激 脑磁图-脑脊液和随后的血小板数量增加有很大的临床意义 抗癌药物引起的血小板减少症在治疗中的意义 抗艾滋病毒治疗。多克隆抗体和单抗的制备 这一阶段提出的对MEG-CSF的SBIR将有助于纯化 用亲和层析法表达MEG-CSF，并鉴定 表达Meg-CSF基因的重组克隆。此外，这种抗体 将使检测方法的发展成为可能，例如一种酶联法 免疫吸附试验(ELISA法)，测定血清或尿液中的MEG-CSF水平 接受化疗或患有血小板减少症的患者 其他原因。将对兔子进行免疫以获得多克隆抗体 并建议对小鼠进行体外和体内免疫 产生单抗。

The production of megakaryocytes from progenitor cells in the marrow can be stimulated by a lineage-specific factor - megakaryocyte colony-stimulating factor (Meg-CSF). The lineage-specific stimulation of megakaryocytes by Meg-CSF and subsequent increase in platelet number has great clinical significance in treating thrombocytopenia resulting from anti-cancer or anti-HIV therapies. The production of polyclonal and monoclonal antibodies to Meg-CSF proposed by this Phase I SBIR would facilitate the purification of Meg-CSF by affinity chromatography, and the identification of recombinant clones expressing Meg-CSF cDNA. In addition, such antibodies will enable the development of assays, such as an enzyme-linked immunosorbent assay (ELISA), to determine serum or urine Meg-CSF levels in those patients undergoing chemotherapy or who have thrombocytopenia from other causes. Rabbits will be immunized to obtain polyclonal antibodies and both in vitro and in vivo immunization of mice is proposed for monoclonal antibody production.